What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
The company also highlighted progress for thyroid eye disease programs, including a June 30, 2026 PDUFA date for veligrotug and ongoing Phase 3 trials for elegrobart. We'll now examine how Viridian's advancing thyroid eye disease pipeline and detailed 2025 results shape the company's evolving investment narrative. Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution. What Is Viridian Therapeutics' Investment Narrative? To own Viridian here, you have to believe its thyroid eye disease franchise can convert today's heavy investment and losses into a viable commercial business. The latest numbers underscore that tension: full-year 2025 revenue stepped up to US$70.85 million, but the net loss widened to US$342.6 million, reinforcing how dependent the story is on veligrotug's June 30, 2026 PDUFA decision and the upcoming Phase 3 readouts for elegrobart. The PDUFA date, EMA filing and clear timelines ke
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $45.00 to $42.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
- Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]BNN Bloomberg
- Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.MarketBeat
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4/A
- VRDN's page on the SEC website